IP Library › Granted Patent US 10,584,128
Granted Patent B2
US 10,584,128 · App. 15/850,720 · Granted Mar 10, 2020

Bicyclic dihydropyrimidine-carboxamide derivatives as Rho-Kinase inhibitors

Inventors: Alessandro Accetta (Parma, IT); Fabio Rancati (Parma, IT); Anna Maria Capelli (Parma, IT); David Edward Clark (Saffron Walden, GB); Patrizia Tisselli (Saffron Walden, GB); Christine Edwards (Saffron Walden, GB); Gurdip Bhalay (Saffron Walden, GB)
Assignee: CHIESI FARMACEUTICI S.p.A.
C07D487/04A61K9/0073A61K31/519A61K45/06A61P11/00A61P11/06A61P37/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,584,128
App. No.
15/850,720
Granted
Mar 10, 2020
Kind
B2
Abstract

Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and pulmonary arterial hypertension (PAH).

Claims (508)

1. A compound of formula (I):

wherein

X 1 and X 2 are in each occurrence independently a carbon atom or a nitrogen atom;

each R, when present, is:

—H

—CN,

halogen,

—NR 5 R 6 ,

(C 1 -C 6 ) alkyl,

(C 1 -C 6 ) haloalkyl,

(C 1 -C 6 ) hydroxyalkyl,

(C 1 -C 6 ) aminoalkyl,

(C 3 -C 10 ) cycloalkyl,

(C 2 -C 6 ) alkenyl,

(C 5 -C 7 ) cycloalkenyl,

(C 2 -C 6 ) alkynyl,

(C 2 -C 6 ) hydroxyalkynyl,

hydroxycarbonyl,

—OR 7

(C 1 -C 6 ) alkylthio,

(C 1 -C 6 ) alkoxy-(C 1 -C 6 ) alkyl,

(C 1 -C 6 ) alkoxycarbonyl,

(C 1 -C 6 ) aminoalkylcarbonyl,

carbamoyl,

(C 3 -C 6 ) cycloalkyl-(C 1 -C 6 ) alkyl,

(C 3 -C 6 ) heterocycloalkyl-(C 1 -C 6 ) alkyl,

aryl,

heteroaryl, or

(C 3 -C 6 ) heterocycloalkyl;

wherein any of said (C 3 -C 6 ) cycloalkyl, aryl, heteroaryl, and (C 3 -C 6 ) heterocycloalkyl is optionally and independently substituted with one or more groups selected from the group consisting of

halogen,

—OH,

(C 1 -C 6 ) alkyl,

(C 1 -C 6 ) haloalkyl,

(C 1 -C 6 ) hydroxyalkyl,

(C 1 -C 6 ) aminoalkyl,

(C 3 -C 10 ) cycloalkyl,

(C 2 -C 6 ) alkenyl,

(C 5 -C 7 ) cycloalkenyl,

(C 2 -C 6 ) alkynyl,

(C 2 -C 6 ) hydroxyalkynyl,

(C 1 -C 6 ) alkoxyl, and

(C 1 -C 6 ) aminoalkylcarbonyl;

R 5 and R 6 are in each occurrence independently selected from the group consisting of

H,

(C 1 -C 6 ) alkyl,

(C 1 -C 6 ) haloalkyl,

(C 1 -C 6 ) hydroxyalkyl,

(C 1 -C 6 ) aminoalkyl,

(C 1 -C 6 ) alkoxyl,

(C 1 -C 6 ) alkoxy-(C 1 -C 6 ) alkyl,

(C 3 -C 6 ) heterocycloalkyl-(C 1 -C 6 ) alkyl,

(C 3 -C 6 ) heterocycloalkyloxyl alkanoyl,

aryl,

heteroaryl, and

(C 3 -C 6 ) heterocycloalkyl;

wherein any of said aryl, heteroaryl, and (C 3 -C 6 ) heterocycloalkyl is optionally and independently substituted with one or more groups selected from the group consisting of

halogen,

—OH, and

(C 1 -C 6 ) alkyl; or

R 5 and R 6 taken together with the nitrogen atom they are linked to form a 4 to 6 membered heterocyclic radical, wherein at least one further ring carbon atom in the said heterocyclic radical may be replaced by at least one heteroatom selected from the group consisting of N, S, or O; and said heterocyclic radical can be further optionally substituted by a group selected from the group consisting of

H,

—CN,

halogen,

-oxo,

—NR 5 R 6

(C 1 -C 6 ) alkyl,

(C 1 -C 6 ) haloalkyl,

(C 1 -C 6 ) hydroxyalkyl,

(C 1 -C 6 ) aminoalkyl,

(C 1 -C 6 ) alkoxyl,

(C 1 -C 6 ) alkoxy-(C 1 -C 6 ) alkyl, and

alkanoyl;

R 7 is in each occurrence independently selected from the group the group consisting of

H,

(C 1 -C 6 ) alkyl,

(C 1 -C 6 ) haloalkyl,

(C 1 -C 6 ) hydroxyalkyl,

(C 1 -C 6 ) aminoalkyl,

(C 1 -C 6 ) alkoxy-(C 1 -C 6 ) alkyl,

(C 3 -C 6 ) heterocycloalkyl-(C 1 -C 6 ) alkyl,

aryl,

heteroaryl, and

(C 3 -C 6 ) heterocycloalkyl;

wherein any of said aryl, heteroaryl, and (C 3 -C 6 ) heterocycloalkyl is optionally and independently substituted with one or more groups selected from the group consisting of

halogen,

—OH, and

(C 1 -C 6 ) alkyl;

p is zero or 1 or 2;

R 1 is selected from the group consisting of

(C 1 -C 6 ) alkyl,

(C 1 -C 6 ) haloalkyl,

(C 1 -C 6 ) hydroxyalkyl,

(C 1 -C 6 ) aminoalkyl,

(C 3 -C 10 ) cycloalkyl,

(C 2 -C 6 ) alkenyl,

(C 5 -C 7 ) cycloalkenyl,

(C 2 -C 6 ) alkynyl,

(C 2 -C 6 ) hydroxyalkynyl,

(C 3 -C 6 ) cycloalkyl-(C 1 -C 6 ) alkyl,

(C 3 -C 6 ) heterocycloalkyl-(C 1 -C 6 ) alkyl,

aryl (C 1 -C 6 ) alkyl,

aryl,

heteroaryl, and

(C 3 -C 6 ) heterocycloalkyl;

each of which cycloalkyl, cycloalkenyl, aryl, heteroaryl, and (C 3 -C 6 ) heterocycloalkyl is optionally and independently substituted with one or more groups selected from the group consisting of

nitro,

halogen,

—NR 5 R 6 ,

—CN,

—OH,

—S(O) 2 —(C 1 -C 6 ) alkyl,

(C 1 -C 6 ) alkyl,

(C 1 -C 6 ) haloalkyl,

(C 1 -C 6 ) alkoxyl,

(C 1 -C 6 ) haloalkoxyl,

(C 1 -C 6 ) aminoalkoxyl,

(C 1 -C 6 ) hydroxyalkoxyl,

(C 3 -C 6 ) heterocycloalkyloxyl,

(C 3 -C 6 ) heterocycloalkyl (C 1 -C 6 ) alkoxyl,

carbamoyl,

alkanoyl,

aryloxyl,

aryl (C 1 -C 6 ) alkoxyl,

aryloxy-(C 1 -C 6 ) alkyl

(C 1 -C 6 ) alkoxycarbonyl,

(C 1 -C 6 ) alkoxy-(C 1 -C 6 ) alkyl,

(C 1 -C 6 ) alkoxycarbonyl-amino-,

(C 1 -C 6 ) hydroxyalkyl,

(C 2 -C 6 ) alkenyl,

(C 2 -C 6 ) alkynyl,

(C 2 -C 6 ) hydroxyalkynyl,

aryl,

heteroaryl, and

(C 3 -C 6 ) heterocycloalkyl;

R 2 is

(C 1 -C 6 ) alkyl,

(C 1 -C 6 ) haloalkyl,

(C 1 -C 6 ) hydroxyalkyl,

(C 1 -C 6 ) aminoalkyl,

(C 3 -C 10 ) cycloalkyl,

(C 1 -C 6 ) alkoxyl, or

(C 1 -C 6 ) alkoxy-(C 1 -C 6 ) alkyl;

A is 1H-indazol-5yl, 6-fluoro-1H-indazole-5yl, isoquinoline-6yl, thieno[2,3-c]pyridine-2yl, thieno[3,2-c]pyridine-2yl, [1,2,4]triazolo[4,3-a]pyridine-7yl, or 1,6-naphthyridin-2-yl each of which is optionally substituted by one or more groups selected from the group consisting of

halogen,

—OH,

(C 1 -C 6 ) alkyl,

(C 1 -C 6 ) alkoxyl,

(C 2 -C 6 ) alkenyl,

(C 2 -C 6 ) alkynyl,

aryl,

heteroaryl, and

(C 3 -C 6 ) heterocycloalkyl;

each of which aryl, heteroaryl, and (C 3 -C 6 ) heterocycloalkyl being further optionally substituted,

or a pharmaceutically acceptable salt thereof.

2. A compound or salt according to claim 1 , wherein each of X 1 and X 2 is a carbon atom, represented by the formula Ia:

wherein R 3 and R 4 are in each occurrence independently selected from the group consisting of

—H

—CN,

halogen,

—NR 5 R 6 ,

(C 3 -C 6 ) alkyl,

(C 1 -C 6 ) haloalkyl,

(C 1 -C 6 ) hydroxyalkyl,

(C 1 -C 6 ) aminoalkyl,

(C 3 -C 10 ) cycloalkyl,

(C 2 -C 6 ) alkenyl,

(C 5 -C 7 ) cycloalkenyl,

(C 2 -C 6 ) alkynyl,

(C 2 -C 6 ) hydroxyalkynyl,

hydroxycarbonyl,

—OR 7

(C 1 -C 6 ) alkylthio,

(C 1 -C 6 ) alkoxy-(C 1 -C 6 ) alkyl,

(C 1 -C 6 ) alkoxycarbonyl,

(C 1 -C 6 ) aminoalkylcarbonyl,

carbamoyl,

aryl,

heteroaryl, and

(C 3 -C 6 ) heterocycloalkyl;

wherein any of said aryl, heteroaryl, and (C 3 -C 6 ) heterocycloalkyl optionally and independently substituted with one or more groups selected from the group consisting of

halogen,

—OH,

(C 1 -C 6 ) alkyl,

(C 1 -C 6 ) haloalkyl,

(C 1 -C 6 ) hydroxyalkyl,

(C 1 -C 6 ) aminoalkyl,

(C 3 -C 10 ) cycloalkyl,

(C 2 -C 6 ) alkenyl,

(C 5 -C 7 ) cycloalkenyl,

(C 2 -C 6 ) alkynyl,

(C 2 -C 6 ) hydroxyalkynyl,

(C 1 -C 6 ) alkoxyl, and

(C 1 -C 6 ) aminoalkylcarbonyl.

3. A compound or salt according to claim 1 , wherein p is 0 and each of X 1 and X 2 is nitrogen, represented by the formula Ib:

4. A compound or salt according to claim 2 , wherein:

A is isoquinoline-6yl, 4-methylisoquinolin-6-yl, or 1H-indazole-5yl

R 3 is in each occurrence independently H or selected from the group consisting of

—CN,

halogen,

ethoxycarbonyl,

aminocarbonyl, N-(2-(dimethylamino)ethyl)aminocarbonyl, and

4-methylpiperazine-1-carbonyl; and

R 4 is in each occurrence independently selected from the group consisting of

—H

amino,

4-methylpiperazin-1-yl,

3-(piperidin-1-yl)propanamido,

2-(pyrrolidin-1-yl)acetamido,

((1-methylpiperidin-4-yl)oxy)acetamido;

—CN,

halogen,

methyl,

ethyl,

propyl,

isopropyl,

trifluoromethyl,

hydroxymethyl,

aminomethyl,

dimethylaminomethyl,

2-(N,N-dimethylamino)ethyl,

N-methyl-N-(2 methoxyethyl)-2-aminoethyl,

2-(N-methyl-N-((1-methylpiperidin-4-yl)methyl)amino)ethyl,

3-methoxyazetidinyl-ethyl,

3-(N,N-dimethyl amino methyl)azetidinyl-ethyl,

3-(methoxymethyl)azetidinyl-ethyl,

N-pyrrolidinyl-ethyl,

N-piperidinyl-ethyl,

4-methoxypiperidinyl-ethyl,

4-(pyrrolidin-1-yl)piperidinyl-ethyl,

4-methylpiperazin-N-yl-ethyl,

(1-acetylpiperazin-4-yl)-ethyl,

morpholin-N-yl-ethyl,

(thiomorpholine 1,1-dioxide)4yl-ethyl,

(8-methyl-2,8-diazaspiro[4.5]decan-2-yl)ethyl,

(3-(piperidin-1-yl)propanamido)methyl,

hydroxycarbonyl,

methylthio,

methoxymethyl,

ethoxycarbonyl,

aminocarbonyl,

N,N dimethyl-aminocarbonyl,

(3,3-difluorocyclobutyl)-aminocarbonyl,

piperazine-1-carbonyl,

morpholine-N-carbonyl,

morpholine-N-carbonyl,

N-(2-(dimethylamino)ethyl)aminocarbonyl,

N-(2-(dimethylamino)ethyl)-N-methylaminocarbonyl,

N-(3-(dimethylamino)propyl)-N-methylaminocarbonyl,

4-methylpiperazine-1-carbonyl,

4-(dimethylamino)piperidin-1-carbonyl,

N-(2-(4-methylpiperazin-1-yl)ethyl)aminocarbonyl,

(2 morpholino-ethyl) aminocarbonyl,

N-methyl-N-(2 morpholino-ethyl) aminocarbonyl,

N-(2-(piperidin-1-yl)ethyl) aminocarbonyl,

N-methyl-N-(2-(piperidin-1-yl)ethyl)aminocarbonyl,

N-(1-methylpiperidin-4-yl-methyl) aminocarbonyl,

N-methyl-N-(1-methylpiperidin-4-yl)aminocarbonyl,

N-methyl-N-(1-methylpiperidin-4-yl)aminocarbonyl,

5-methyloctahydropyrrolo[3,4-c]pyrrole-2 carbonyl,

N-cyclopropyl-aminocarbonyl,

(piperidin-1-yl)ethyl aminocarbonyl,

p-methoxy-phenyl,

m-methoxy-phenyl,

o-methoxy-phenyl,

oxetan-3-yl, and

(2-(piperidin-1-yl)ethylcarbonyl)piperidin-4-yl;

R 1 is selected from the group consisting of

isopentanyl

cyclohexanyl,

4-(trifluoromethyl)cyclohexyl,

adamantan-yl

phenylethyl,

p-methylphenyl,

4-(tert-butyl)phenyl,

4-(hydroxy)phenyl,

p-fluorophenyl,

p-chlorophenyl,

p-bromophenyl,

4-chloro-2-fluoro-phenyl,

4-chloro-3-fluoro-phenyl,

3-fluoro-4-hydroxyphenyl,

4-(trifluoromethyl)phenyl,

3-fluoro-4-(trifluoromethyl)phenyl,

2,3-difluoro-4-(trifluoromethyl)phenyl,

4-chloro-3-(trifluoromethyl)phenyl,

3-methoxy-phenyl,

2,3-dihydro-1H-inden-2yl,

3-phenoxyphenyl,

2,3-difluoro-4-methylphenyl,

3-fluoro-4-methylphenyl,

4-(difluoromethyl)-3-fluorophenyl,

piperidinyl,

2,3-dihydrobenzo[b][1,4]dioxine-2yl,

benzo[d]thiazol-2yl,

2-chloro-5-pyridinyl,

1H-indole-6yl,

2-phenylthiazol-5yl,

2-phenyloxazole-5yl,

benzo[b]thiophene-6yl,

1-methyl-1H-benzo[d]imidazole-6yl,

1-methylpiperidin-4-yl, and

morpholin-N-yl;

R 2 is methyl, cyclopropyl, or methoxymethyl.

5. A compound according to claim 3 , wherein:

A is 1H-indazole-5yl;

R 1 is p-fluorophenyl, p-chlorophenyl, 4-(trifluoromethyl)phenyl, or 3-fluoro-4-(trifluoromethyl)phenyl; and

R 2 is methyl.

6. A compound or salt according to claim 1 , which is a compound selected from the group consisting of:

ethyl 6-(isoquinolin-6-ylcarbamoyl)-5-methyl-7-(4-(trifluoromethyl)phenyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

ethyl 6-((1H-indazol-5-yl)carbamoyl)-5-methyl-7-(4-(trifluoromethyl)phenyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

ethyl 6-((1H-indazol-5-yl)carbamoyl)-5-methyl-7-(p-tolyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

ethyl 6-((1H-indazol-5-yl)carbamoyl)-7-(4-fluorophenyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

ethyl 6-((1H-indazol-5-yl)carbamoyl)-7-(6-chloropyridin-3-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

ethyl 6-((1H-indazol-5-yl)carbamoyl)-7-(3-methoxyphenyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

ethyl 6-((1H-indazol-5-yl)carbamoyl)-7-(4-chloro-2-fluorophenyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

ethyl 7-(benzo[d]thiazol-2-yl)-6-(isoquinolin-6-ylcarbamoyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

ethyl 7-(4-hydroxyphenyl)-6-(isoquinolin-6-ylcarbamoyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

ethyl 7-(3-fluoro-4-hydroxyphenyl)-6-(isoquinolin-6-ylcarbamoyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

ethyl 6-((1H-indazol-5-yl)carbamoyl)-5-methyl-7-(tetrahydro-2H-pyran-4-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

ethyl 6-((1H-indazol-5-yl)carbamoyl)-5-methyl-7-(1-methylpiperidin-4-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

ethyl 6-((1H-indazol-5-yl)carbamoyl)-7-isobutyl-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

ethyl 6-((1H-indazol-5-yl)carbamoyl)-7-cyclohexyl-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

ethyl 6-([1,2,4]triazolo[4,3-a]pyridin-7-ylcarbamoyl)-7-(3-fluoro-4-(trifluoromethyl)phenyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

ethyl 6-((1H-indazol-5-yl)carbamoyl)-3-cyano-5-methyl-7-(4-(trifluoromethyl)phenyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

ethyl 6-((1H-indazol-5-yl)carbamoyl)-7-(4-fluorophenyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate;

3-cyano-7-(4-fluorophenyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(4-fluorophenyl)-N6-(1H-indazol-5-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-3,6-dicarboxamide;

7-(4-fluorophenyl)-N-(1H-indazol-5-yl)-2-(4-methoxyphenyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(4-fluorophenyl)-N-(1H-indazol-5-yl)-2-(2-methoxyphenyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

3-bromo-7-(4-fluorophenyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(4-fluorophenyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(4-chlorophenyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(2-fluoro-4-(trifluoromethyl)phenyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxamide;

N-(1H-indazol-5-yl)-5-methyl-7-(4-(trifluoromethyl)phenyl)-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(4-fluorophenyl)-N-(1H-indazol-5-yl)-2,5-dimethyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-(tert-butyl)-7-(4-fluorophenyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-bromo-7-(4-fluorophenyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-cyano-7-(4-fluorophenyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(6-chloropyridin-3-yl)-N-(1H-indazol-5-yl)-5-methyl-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

N-(1H-indazol-5-yl)-5-methyl-7-(1-methylpiperidin-4-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-cyano-N-(1H-indazol-5-yl)-5-methyl-7-(4-(trifluoromethyl)phenyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

N-(1H-indazol-5-yl)-2-(methoxymethyl)-5-methyl-7-(4-(trifluoromethyl)phenyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-2-(methoxymethyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-(2-(dimethylamino)ethyl)-7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(1H-indol-6-yl)-N-(isoquinolin-6-yl)-2-(methoxymethyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(6-chloropyridin-3-yl)-N-(6-fluoro-1H-indazol-5-yl)-5-methyl-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

N-(6-fluoro-1H-indazol-5-yl)-7-(3-fluoro-4-(trifluoromethyl)phenyl)-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxamide;

ethyl 7-(3-fluoro-4-(trifluoromethyl)phenyl)-5-methyl-6-(thieno[3,2-c]pyridin-2-ylcarbamoyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

ethyl 7-(3-fluoro-4-(trifluoromethyl)phenyl)-5-methyl-6-(thieno[2,3-c]pyridin-2-ylcarbamoyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-7-(4-(trifluoromethyl)phenyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-7-(1-methyl-1H-indol-4-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-7-(1-methyl-1H-benzo[d]imidazol-6-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(benzo[b]thiophen-6-yl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(4-chloro-3-(trifluoromethyl)phenyl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-((3r,5r,7r)-adamantan-1-yl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-7-(2-phenyloxazol-5-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-7-(3-phenoxyphenyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-7-(3-(trifluoromethyl)phenyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-7-(2-phenylthiazol-5-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-7-phenethyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(4-(tert-butyl)phenyl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(4-bromo-3-fluorophenyl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(2,3-difluoro-4-(trifluoromethyl)phenyl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(4-chloro-3-fluorophenyl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-methylphenyl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(2-fluoro-4-methylphenyl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(2,3-dihydro-1H-inden-2-yl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(4-bromophenyl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(4-chlorophenyl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-(hydroxymethyl)-7-(1H-indol-6-yl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(4-chloro-2-fluorophenyl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-7-(p-tolyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-(hydroxymethyl)-N-(1H-indazol-5-yl)-5-methyl-7-(p-tolyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(4-chloro-2-fluorophenyl)-2-(hydroxymethyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-(hydroxymethyl)-N-(1H-indazol-5-yl)-5-methyl-7-(4-(trifluoromethyl)phenyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(6-chloropyridin-3-yl)-2-(hydroxymethyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(4-fluorophenyl)-2-(hydroxymethyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

first stereoisomer of 7-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

second stereoisomer of 7-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

third stereoisomer of 7-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

fourth stereoisomer of 7-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

6-((1H-indazol-5-yl)carbamoyl)-5-methyl-7-(4-(trifluoromethyl)phenyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylic acid;

6-((1H-indazol-5-yl)carbamoyl)-5-methyl-7-(p-tolyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylic acid;

6-((1H-indazol-5-yl)carbamoyl)-7-(4-fluorophenyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylic acid;

N-(1H-indazol-5-yl)-5-methyl-2-(4-methylpiperazine-1-carbonyl)-7-(4-(trifluoromethyl)phenyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N6-(isoquinolin-6-yl)-5-methyl-N2-(2-(piperidin-1-yl)ethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2,6-dicarboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N6-(isoquinolin-6-yl)-N2,5-dimethyl-N2-(2-(piperidin-1-yl)ethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2,6-dicarboxamide;

N2-(2-(dimethylamino)ethyl)-7-(3-fluoro-4-(trifluoromethyl)phenyl)-N6-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2,6-dicarboxamide;

N2-(2-(dimethylamino)ethyl)-7-(3-fluoro-4-(trifluoromethyl)phenyl)-N6-(isoquinolin-6-yl)-N2,5-dimethyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2,6-dicarboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N6-(isoquinolin-6-yl)-5-methyl-N2-(2-(4-methylpiperazin-1-yl)ethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2,6-dicarboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N6-(isoquinolin-6-yl)-5-methyl-N2-(2-morpholinoethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2,6-dicarboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N6-(isoquinolin-6-yl)-N2,5-dimethyl-N2-(2-morpholinoethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2,6-dicarboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N6-(isoquinolin-6-yl)-5-methyl-N2-((1-methylpiperidin-4-yl)methyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2,6-dicarboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N6-(isoquinolin-6-yl)-N2,5-dimethyl-N2-((1-methylpiperidin-4-yl)methyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2,6-dicarboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-2-(5-methyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-(4-(dimethylamino)piperidine-1-carbonyl)-7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N6-(isoquinolin-6-yl)-N2,5-dimethyl-N2-(1-methylpiperidin-4-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2,6-dicarboxamide;

N2-(3-(dimethylamino)propyl)-7-(3-fluoro-4-(trifluoromethyl)phenyl)-N6-(isoquinolin-6-yl)-N2,5-dimethyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2,6-dicarboxamide;

7-(4-fluorophenyl)-N-(1H-indazol-5-yl)-5-methyl-2-(morpholine-4-carbonyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(4-fluorophenyl)-N-(1H-indazol-5-methyl-3-(4-methylpiperazine-1-carbonyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

N3-(2-(dimethylamino)ethyl)-7-(4-fluorophenyl)-N6-(1H-indazol-5-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(4-fluorophenyl)-N-(1H-indazol-5-yl)-5-methyl-2-(piperazine-1-carbonyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-((dimethylamino)methyl)-7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-2-(morpholinomethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-2-((4-methylpiperazin-1-yl)methyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-2-(piperidin-1-ylmethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-2-(((2-methoxyethyl)(methyl)amino)methyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-2-((4-methoxypiperidin-1-yl)methyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-2-((3-methoxyazetidin-1-yl)methyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-2-((3-(methoxymethyl)azetidin-1-yl)methyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-2-(pyrrolidin-1-ylmethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-2-((8-methyl-2,8-diazaspiro[4.5]decan-2-yl)methyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-2-((methyl((1-methylpiperidin-4-yl)methyl)amino)methyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-2-((4-(pyrrolidin-1-yl)piperidin-1-yl)methyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-((3-((dimethylamino)methyl)azetidin-1-yl)methyl)-7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

N-(1H-indazol-5-yl)-5-methyl-2-(morpholinomethyl)-7-(4-(trifluoromethyl)phenyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-((1,1-dioxidothiomorpholino)methyl)-7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-((4-acetylpiperazin-1-yl)methyl)-7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-((dimethylamino)methyl)-7-(3-fluoro-4-methylphenyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-(aminomethyl)-N-(1H-indazol-5-yl)-5-methyl-7-(4-(trifluoromethyl)phenyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-(aminomethyl)-7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

first eluting enantiomer of ethyl 6-((1H-indazol-5-yl)carbamoyl)-7-(4-fluorophenyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

second eluting enantiomer of ethyl 6-(1H-indazol-5-yl)carbamoyl)-7-(4-fluorophenyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

first eluting enantiomer of ethyl 6-((1H-indazol-5-yl)carbamoyl)-7-(4-chloro-2-fluorophenyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

second eluting enantiomer of ethyl 6-((1H-indazol-5-yl)carbamoyl)-7-(4-chloro-2-fluorophenyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

first eluting enantiomer of 7-(4-fluorophenyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxamide;

second eluting enantiomer of 7-(4-fluorophenyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxamide;

first eluting enantiomer of 7-(4-chlorophenyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxamide;

second eluting enantiomer of 7-(4-chlorophenyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxamide;

first eluting enantiomer of 7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxamide;

second eluting enantiomer of 7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxamide;

first eluting enantiomer of 7-(2-fluoro-4-(trifluoromethyl)phenyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxamide;

second eluting enantiomer of 7-(2-fluoro-4-(trifluoromethyl)phenyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxamide;

first eluting enantiomer of N-(1H-indazol-5-yl)-5-methyl-7-(4-(trifluoromethyl)phenyl)-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxamide;

second eluting enantiomer of N-(1H-indazol-5-yl)-5-methyl-7-(4-(trifluoromethyl)phenyl)-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxamide;

first eluting enantiomer of 7-(6-chloropyridin-3-yl)-N-(1H-indazol-5-yl)-5-methyl-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

second eluting enantiomer of 7-(6-chloropyridin-3-yl)-N-(1H-indazol-5-yl)-5-methyl-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

first eluting enantiomer of N-(6-fluoro-1H-indazol-5-yl)-7-(3-fluoro-4-(trifluoromethyl)phenyl)-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxamide;

second eluting enantiomer of N-(6-fluoro-1H-indazol-5-yl)-7-(3-fluoro-4-(trifluoromethyl)phenyl)-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxamide;

first eluting enantiomer of 2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-7-(4-(trifluoromethyl)phenyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

second eluting enantiomer of 2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-7-(4-(trifluoromethyl)phenyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(2,3-dihydro-1H-inden-2-yl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(2,3-dihydro-1H-inden-2-yl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

first eluting enantiomer of 7-(4-bromophenyl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

second eluting enantiomer of 7-(4-bromophenyl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

first eluting enantiomer of 7-(4-chlorophenyl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

second eluting enantiomer of 7-(4-chlorophenyl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

first eluting enantiomer of 7-(3-fluoro-4-(trifluoromethyl)phenyl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

second eluting enantiomer of 7-(3-fluoro-4-(trifluoromethyl)phenyl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

first eluting enantiomer of 2-(hydroxymethyl)-N-(1H-indazol-5-yl)-5-methyl-7-(4-(trifluoromethyl)phenyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

second eluting enantiomer of (S)-2-(hydroxymethyl)-N-(1H-indazol-5-yl)-5-methyl-7-(4-(trifluoromethyl)phenyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

first eluting enantiomer of 7-(4-fluorophenyl)-2-(hydroxymethyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

second eluting enantiomer of 7-(4-fluorophenyl)-2-(hydroxymethyl)-N-(1H-indazol-5-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

first eluting enantiomer of 7-(3-fluoro-4-(trifluoromethyl)phenyl)-N6-(isoquinolin-6-yl)-N2,5-dimethyl-N2-(2-(piperidin-1-yl)ethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2,6-dicarboxamide;

second eluting enantiomer of 7-(3-fluoro-4-(trifluoromethyl)phenyl)-N6-(isoquinolin-6-yl)-N2,5-dimethyl-N2-(2-(piperidin-1-yl)ethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2,6-dicarboxamide;

first eluting enantiomer of 2-((dimethylamino)methyl)-7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

second eluting enantiomer of 2-((dimethylamino)methyl)-7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

first eluting enantiomer of 7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-2-((4-methylpiperazin-1-yl)methyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

second eluting enantiomer of 7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-2-((4-methylpiperazin-1-yl)methyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

first eluting enantiomer of 7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-2-(piperidin-1-ylmethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

second eluting enantiomer of 7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-2-(piperidin-1-ylmethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

first eluting enantiomer of 7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-2-((methyl((1-methylpiperidin-4-yl)methyl)amino)methyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

second eluting enantiomer of 7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-2-((methyl((1-methylpiperidin-4-yl)methyl)amino)methyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

first eluting enantiomer of 2-((dimethylamino)methyl)-7-(3-fluoro-4-methylphenyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

second eluting enantiomer of 2-((dimethylamino)methyl)-7-(3-fluoro-4-methylphenyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

ethyl 6-((1,6-naphthyridin-2-yl)carbamoyl)-7-(3-fluoro-4-(trifluoromethyl)phenyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

ethyl 7-(3-fluoro-4-(trifluoromethyl)phenyl)-5-methyl-6-((4-methylisoquinolin-6-yl)carbamoyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

ethyl 7-(4-(difluoromethyl)-3-fluorophenyl)-6-(isoquinolin-6-ylcarbamoyl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylate;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-2-(oxetan-3-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-2-(methylthio)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

5-cyclopropyl-7-(3-fluoro-4-(trifluoromethyl)phenyl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-2-(hydroxymethyl)-N-(isoquinolin-6-yl)-5-(methoxymethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-((dimethylamino)methyl)-N-(isoquinolin-6-yl)-5-methyl-7-(4-(trifluoromethyl)cyclohexyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(2,3-difluoro-4-methylphenyl)-2-((dimethylamino)methyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(2,3-difluoro-4-(trifluoromethyl)phenyl)-2-((dimethylamino)methyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

2-((dimethylamino)methyl)-7-(3-fluoro-4-(trifluoromethyl)phenyl)-5-methyl-N-(1,6-naphthyridin-2-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(2,3-dihydro-1H-inden-2-yl)-2-((dimethylamino)methyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

N2-cyclopropyl-7-(3-fluoro-4-(trifluoromethyl)phenyl)-N6-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2,6-dicarboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N6-(isoquinolin-6-yl)-N2,N2,5-trimethyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2,6-dicarboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N6-(isoquinolin-6-yl)-5-methyl-N2-(3-oxo-3-(pyrrolidin-1-yl)propyl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-2,6-dicarboxamide;

N2-(3,3-difluorocyclobutyl)-7-(3-fluoro-4-(trifluoromethyl)phenyl)-N6-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-2,6-dicarboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N6-(isoquinolin-6-yl)-5-methyl-N2-(2-(piperidin-1-yl)ethyl)-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-2,6-dicarboxamide;

2-amino-7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-2-(3-(piperidin-1-yl)propanamido)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-2-(2-(pyrrolidin-1-yl)acetamido)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-2-(2-((1-methylpiperidin-4-yl)oxy)acetamido)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-methylphenyl)-N-(isoquinolin-6-yl)-5-methyl-2-(2-(pyrrolidin-1-yl)acetamido)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-2-(1-(3-(piperidin-1-yl)propanoyl)piperidin-4-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

7-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(isoquinolin-6-yl)-5-methyl-2-(4-methylpiperazin-1-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

first eluting enantiomer of 7-(2,3-difluoro-4-(trifluoromethyl)phenyl)-2-((dimethylamino)methyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

second eluting enantiomer of 7-(2,3-difluoro-4-(trifluoromethyl)phenyl)-2-((dimethylamino)methyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

second eluting enantiomer of 7-(2,3-difluoro-4-methylphenyl)-2-((dimethylamino)methyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

first eluting enantiomer of 7-(2,3-dihydro-1H-inden-2-yl)-2-((dimethylamino)methyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

second eluting enantiomer of 7-(2,3-dihydro-1H-inden-2-yl)-2-((dimethylamino)methyl)-N-(isoquinolin-6-yl)-5-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxamide;

first eluting enantiomer of 7-(3-fluoro-4-(trifluoromethyl)phenyl)-N6-(isoquinolin-6-yl)-5-methyl-N2-(2-(piperidin-1-yl)ethyl)-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-2,6-dicarboxamide; and

second eluting enantiomer of 7-(3-fluoro-4-(trifluoromethyl)phenyl)-N6-(isoquinolin-6-yl)-5-methyl-N2-(2-(piperidin-1-yl)ethyl)-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-2,6-dicarboxamide;

or a pharmaceutically acceptable salt of said compound.

7. A pharmaceutical composition, comprising a compound or salt according to claim 1 , either alone or in combination with another one or more other active ingredients, in admixture with one or more pharmaceutically acceptable carriers or excipients.

8. A method for the treatment of a pulmonary disease, said method comprising administering an effective amount of a compound or salt according to claim 1 to a subject in need thereof.

9. A method according to claim 8 , wherein said pulmonary disease is asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, or pulmonary hypertension.

10. A method according to claim 8 , wherein said pulmonary disease is pulmonary arterial hypertension.

11. A combination, comprising a compound or salt according to claim 1 and one or more active ingredients selected from the group consisting of an organic nitrate, a NO donor, inhaled NO; a stimulator of soluble guanylate cyclase (sGC), a prostaciclin analogue PGI2, an agonist of a prostacyclin receptor, a compound that inhibits the degradation of cyclic guanosine monophosphate (cGMP) and/or cyclic adenosine monophosphate (cAMP), a human neutrophilic elastase inhibitor, a compound which inhibits the signal transduction cascade, an active substance for lowering blood pressure, a neutral endopeptidase inhibitor, an osmotic agents, an ENaC blocker, an anti-inflammatory, a bronchodilatory, an antihistamine drug, an anti-tussive drug, an antibiotic, a DNase drug substance and selective cleavage agents, an agent that inhibits ALK5 and/or ALK4 phosphorylation of Smad2 and Smad3, a tryptophan hydroylase 1 (TPH1) inhibitor, and a multi-kinase inhibitor.

12. A pharmaceutical composition according to claim 7 , which is in a form suitable to be administered by inhalation, such as inhalable powders, propellant-containing metering aerosols or propellant-free inhalable formulations.

13. A pharmaceutical composition according to claim 7 , which is an inhalable powder, a propellant-containing metering aerosol, or a propellant-free inhalable formulation.

14. A device, comprising a pharmaceutical composition according to claim 7 , which is a single-dose dry powder inhaler, a multi-dose dry powder inhaler, a metered dose inhaler, or a soft mist nebulizer.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2018
From: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LTD.
To: CHIESI FARMACEUTICI S.P.A.
Reel/Frame 045744/0066 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2018
From: ACCETTA, ALESSANDRO; RANCATI, FABIO; CAPELLI, ANNA MARIA
To: CHIESI FARMACEUTICI S.P.A.
Reel/Frame 045561/0453 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2018
From: CLARK, DAVID EDWARD; TISSELLI, PATRIZIA; EDWARDS, CHRISTINE; BHALAY, GURDIP
To: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LTD
Reel/Frame 045561/0509 →
Priority Claims (1)
EP 16205661 · Dec 21, 2016 · regional
Continuity (1)
Related Publication 20180170939A1 · Jun 21, 2018